Full history for every metric is available with a Kvantra account
CardieX Limited (CDX.AX)
Key financial summary
Financials in AUD| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM | ||
|---|---|---|---|---|---|---|---|---|
| Total revenue | AUD m | 4 | 5 | 4 | 5 | 11 | 6 | 6 |
| Operating profit | AUD m | -12 | -12 | |||||
| Net profit | AUD m | -3 | -6 | -12 | -19 | -7 | -13 | -13 |
| EPS reported | AUD | -0.04 | -0.04 | |||||
| Operating cashflow per share | AUD | -0.03 | -0.03 | |||||
| Capex per share | AUD | 0.00 | 0.00 | |||||
| FCF per share | AUD | -0.03 | -0.03 | |||||
| Free cash flow | AUD m | -11 | -11 | |||||
| Net debt | AUD m | 1 | 1 | |||||
| Book value equity | AUD m | 6 | 6 | |||||
| Book value per share | AUD | 0.02 | 0.01 | |||||
| Number of shares | m | 354.14 | 412.06 | |||||
| DPS (TTM paid) | AUD | 0.00 | 0.00 |
Financial summary
Financials in AUD| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM | ||
|---|---|---|---|---|---|---|---|---|
| Value | ||||||||
| P/E TTM | x | - | - | |||||
| P/B LTM | x | 2.53 | 3.54 | |||||
| P/S LTM | x | 2.25 | 3.15 | |||||
| P/FCF LTM | x | -1.30 | -1.81 | |||||
| EV/EBITDA LTM | x | -1.31 | -1.74 | |||||
| EV/Sales LTM | x | 2.45 | 3.28 | |||||
| Earnings Yield LTM | % | -93.36% | -103.74% | |||||
| FCF Yield | % | -77.11% | -55.16% | |||||
| Quality | ||||||||
| ROE | % | -236.19% | -273.06% | |||||
| ROIC | % | -126.67% | -126.67% | |||||
| Operating margin | % | -187.45% | -187.45% | |||||
| Gross margin | % | 78.27% | 78.27% | |||||
| FCF/Sales | % | -173.86% | -173.86% | |||||
| Growth and momentum | ||||||||
| EPS Growth YoY | % | - | - | |||||
| Sales Growth YoY | % | -42.39% | -42.39% | |||||
| Net Income Growth YoY | % | - | - | |||||
| FCF Growth | % | - | - | |||||
| Operating Profit Growth | % | - | - | |||||
| Dividend and capital structure | ||||||||
| Dividend Yield | % | 0.00% | 0.00% | |||||
| Dividend Growth | % | 0.00% | 0.00% | |||||
| Payout Ratio | % | 0.00% | 0.00% | |||||
| FCF/Debt | x | -2.96 | -2.96 | |||||
| Net Debt/EBITDA | x | -0.11 | -0.11 | |||||
| EBIT/Net interest | x | -17.78 | -17.78 | |||||
| Net debt/market cap | % | 5.47% | 3.92% | |||||
| Net debt/Equity | x | 0.14 | 0.14 | |||||
| Gross debt/equity | x | 0.66 | 0.66 | |||||
Company overview
CardieX Limited, established in Sydney, Australia, in 1994, is a global innovator specializing in the design, production, and distribution of medical devices for cardiovascular health management. Operating across the Americas, Europe, and the Asia Pacific, the company collaborates with pharmaceutical firms by providing its advanced SphygmoCor XCEL devices. It also delivers comprehensive laboratory and data management services, ensuring high-quality datasets for clinical trial sponsors. Under its CONNEQT brand, CardieX develops cutting-edge home vascular health solutions, which encompass remote patient monitoring, tools for decentralized clinical trials, specialized wearables, and medical applications. A flagship product is the CONNEQT Pulse device, a home-based system that leverages proprietary SphygmoCor technology to precisely measure central blood pressure, arterial waveforms, and other vital arterial health parameters. CardieX serves a diverse clientele, including hospitals, clinics, research institutions, and pharmaceutical companies. The company also maintains a strategic alliance with LifeQ, Inc., focusing on wearable device technology. CardieX Limited was formerly known as AtCor Medical Holdings Limited until its name change in June 2018.
Similar companies
For informational purposes only. Kvantra provides data and quantitative analysis, not investment advice. KvantraRank is a mechanical model output. Analyst price targets and ratings are sourced from third parties and are not Kvantra recommendations. Past performance does not guarantee future results; all investments carry risk.
CardieX Limited (CDX.AX)
CardieX Limited, established in Sydney, Australia, in 1994, is a global innovator specializing in the design, production, and distribution of medical devices for cardiovascular health management. Operating across the Americas, Europe, and the Asia Pacific, the company collaborates with pharmaceutical firms by providing its advanced SphygmoCor XCEL devices. It also delivers comprehensive laboratory and data management services, ensuring high-quality datasets for clinical trial sponsors. Under its CONNEQT brand, CardieX develops cutting-edge home vascular health solutions, which encompass remote patient monitoring, tools for decentralized clinical trials, specialized wearables, and medical applications. A flagship product is the CONNEQT Pulse device, a home-based system that leverages proprietary SphygmoCor technology to precisely measure central blood pressure, arterial waveforms, and other vital arterial health parameters. CardieX serves a diverse clientele, including hospitals, clinics, research institutions, and pharmaceutical companies. The company also maintains a strategic alliance with LifeQ, Inc., focusing on wearable device technology. CardieX Limited was formerly known as AtCor Medical Holdings Limited until its name change in June 2018.
Unlock all fundamental data
Sign up for FreeUnlock all fundamental data
Sign up for Free